ClinicalTrials.gg
CompletedNCT01340430Updated May 9, 2024

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

A Phase 2 interventional study of Trastuzumab in HER-2 Positive Breast Cancer, sponsored by Lucia Del Mastro,MD. Completed at 6 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-09.

Sponsored by Lucia Del Mastro,MD · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2 (HER2) positive non operable breast cancer

02

Conditions studied

  • HER-2 Positive Breast Cancer

Keywords

  • her2 positive breast cancer
  • her2 positive non operable breast cancer
  • her2 positive locally advanced breast cancer
  • neoadjuvant trastuzumab
  • pathologic complete response
03

In context

Pathologic Complete Response

138 studies on the registry are indexed under Pathologic Complete Response; 57 are open to participants now.

This study's enrollment of 43 is below the median of 85 across 92 interventional studies indexed under Pathologic Complete Response.

Browse Pathologic Complete Response studies →

Lead sponsor

This is the only study on the registry with Lucia Del Mastro,MD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Performance StatusEstearn Cooperative Oncology Group () 0-1
  2. confirmed invasive breast cancer,
  3. Primary tumour greater ≥ 2 cm diameter, measured by clinical examination and mammography or echography or Nuclear Magnetic Resonance (NMR) candidate to chemotherapy ,
  4. Any N,
  5. No evidence of (M0);
  6. Over expression and/or amplification of in the invasive component of the primary tumour according to one of the following definitions:
  7. 3+ over expression by immunohistochemistry (IHC) (> 30% of invasive tumour cells),
  8. 2+ or 3+ (in 30% o less neoplastic cells) overexpression by IHC and in situ hybridization (FISH/CISH) test demonstrating Her2 gene amplication ,
  9. Her 2 gene amplication by FISH/CISH (ratio > 2.2);
  10. Known hormone receptor status
  11. Hematopoietic status:

    1. ≥ 1.5 x 109/L,
    2. count ≥ 100 x 109/L,
  12. Hepatic status:

    1. serum total ≤ 1.5 x . In the case of known Gilbert's syndrome a higher serum total bilirubin (\< 2 x ULN) is allowed,
    2. (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN,
    3. alkaline phosphatase ≤ 2.5 times ULN;
  13. Renal status:

    a. Creatinine ≤ 2.0 mg/dL;

  14. Cardiovascular:

    a. baseline (LVEF) ≥ 50% measured by echocardiography or multigate acquisition scan (MUGA);

  15. For women of negative serum pregnancy test
  16. Written .

Exclusion criteria

Exclusion Criteria:

  1. Male gender
  2. Pregnant or lactating women
  3. Received any prior treatment for primary invasive breast cancer
  4. Known history of uncontrolled or symptomatic angina, arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (> 180/110), unstable diabetes mellitus, dyspnoea at rest or chronic therapy with oxygen;
  5. Active or uncontrolled infection,
  6. Dementia altered mental status or any psychiatric condition that would prevent the under standing or rendering of ,
  7. Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies),
  8. Previous or concomitant within the past 3 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
  9. Concurrent disease or condition that would have make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    FEC-paclitaxel-trastuzumab

    fluorouracil 600 mg/m2; epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2 for 4 cycles followed by paclitaxel 80 mg/m2/week in combination with trastuzumab for 12 weeks

    Drug: Trastuzumab

Interventions

  • neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab

    Also known as: herceptin

06

What researchers measure

Primary outcomes

  1. pathologic complete response

    Time frame: at definitive surgery within 4 weeks after the last dose of paclitaxel and concurrent trastuzumab

Secondary outcomes

  1. safety and tolerability

    safety and tolerability will be assessed by standard clinical and laboratory tests (hematology, serum chemistry). Toxicity grade is defined by the NCI Common Toxicity Criteria (CTC) Adverse Event (AE) v 3.0

    Time frame: one year

  2. cardiotoxicity

    Time frame: one year

  3. disease free survival

    Time frame: one year

  4. overall survival

    Time frame: one year

  5. rate of conversion from radical to conservative surgery

    Time frame: definitive surgery

  6. potential biomarkers of trastuzumab resistance

    Time frame: one year

07

Study locations

6 sites
  • Istituto Nazionale per La Ricerca sul Cancro (IST)
    Genoa, Ge 16132, Italy
  • Ospedale S. Maria della Misericordia - Oncologia Medica
    Perugia, PG 06156, Italy
  • Fondazione del Piemonte per l'Oncologia - IRCC di Candiolo
    Candiolo, TO 10060, Italy
  • Ospedale Ostetrico Ginecologico S. Anna Di Torino - Oncologia Medica
    Torino, To 10100, Italy
  • Ospedale Mauriziano Umberto I - Ginecologia Oncologica
    Torino, TO 10128, Italy
  • Ospedale Sacro Cuore - Don Calabria - Oncologia Medica
    Negrar, VR 37024, Italy
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Dec 2015 and a completion of Jan 2022. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2011
First posted
Apr 22, 2011
Start
Mar 2011
Primary completionActual
Dec 2015
CompletionActual
Jan 2022
Last update
May 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01340430
Lead sponsor
Lucia Del Mastro,MD
Responsible party
Lucia Del Mastro,MD (md, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy) — Sponsor-investigator
First posted
Apr 22, 2011
Start date
Mar 2011
Primary completion
Dec 2015
Completion
Jan 2022
Last update
May 9, 2024

Study contacts

Lucia Del Mastro, MD
principal investigator · National Institute For Cancer Reasearch

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion